FDA Brief

Warning letters Drugs

FDA warning letter to

Nature’s Fusions LLC

High riskIssued Jun 25, 2025Posted Jul 22, 2025Center for Drug Evaluation and Research (CDER)

FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.

What happened

FDA inspected Nature's Fusions' drug manufacturing facility in Orem, Utah, from January 15 to 21, 2025. The agency found that the firm repackaged expired bulk ethanol hand sanitizer gel and assigned a two-year expiry without stability studies, stored bulk totes outdoors since April 2020, did not adequately test incoming isopropyl alcohol or finished batches, and did not validate or monitor its water system. FDA said it had not received a response addressing the inspection deficiencies.

What FDA found

  1. The firm used expired bulk ethanol hand sanitizer gel and assigned a two-year expiry without stability studies, and stored bulk totes outdoors outside the labeled storage range.

    21 CFR 211.166(a) and 21 CFR 211.42(b)
  2. The firm did not test incoming components such as isopropyl alcohol and relied on supplier certificates of analysis instead.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm did not adequately test finished batches for identity, strength, and harmful microorganisms before release; it calculated assay values and used only appearance, color, and odor checks.

    21 CFR 211.165(a) and 211.165(b)
  4. The firm used water for drug manufacturing without adequate validation or monitoring for conductivity, total organic carbon, and harmful microorganisms, and had an elevated microbial count in 2024.

    21 CFR 211.100(a)

What FDA wants

FDA tells Nature's Fusions to correct the violations promptly and respond in writing within 15 working days with actions, prevention plans, and the requested assessments and testing; if it cannot complete corrections, it must give reasons and a schedule. FDA also asks whether the firm will resume drug manufacturing and requires notice before resuming.

Who should pay attention

  • retailers and distributors selling over-the-counter hand sanitizers
  • brands that buy repackaged or contract-manufactured hand sanitizer
  • quality teams managing supplier certificates of analysis and water systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk